The drug-maker's stock just keeps going higher. What is the next move?
Cannabinoids can relieve symptoms, ranging from pain to seizures.
Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.
The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.
Amgen sets to offer a competitor to Roche's Avastin.
A co-founder describes its unique approach to oncology.
The U.S. Food and Drug Administration has approved Bayer to sell a new drug to adults with relapsing follicular lymphoma.
The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.
HCA Healthcare and Universal Health Services are the only outfits capable of buying Tenet in whole, but such a move would run counter to their growth strategies.
The Dow Jones Industrial Average hit a fresh intraday record earlier, but the rest of markets remained shaky after the latest inflation numbers called the Fed's plans into question.
What's next for Tenet Healthcare shares?
Summit Therapeutics and Epizyme are raising cash to fund new drug development.
Despite pleading with his judge through a letter, Martin Shkreli had his $5 million bail revoked and will sit in jail while he awaits sentencing on securities fraud conviction.
Centene on Sept. 12 unveiled a $3.75 billion deal to purchase substantially all of the assets of Fidelis Care. The transaction makes the buyer a less likely takeout candidate.
The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.